First-line antiretroviral therapy in resource-limited settings: time to reconsider?

Journal of Infectious Diseases

Volumn 199, Issue 9, 2009, Pages 1407-

  Adlington, Rebecca ^a,b   Richens, John ^a   Shahmanesh, Maryam ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Off Capper St   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; LOPINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; STAVUDINE;

ANTIVIRAL THERAPY; CONGO; COST EFFECTIVENESS ANALYSIS; GOVERNMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RESOURCE MANAGEMENT; RURAL HEALTH CARE; WORLD HEALTH ORGANIZATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; STAVUDINE;

EID: 65649090913     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/597809     Document Type: Letter

References (5)

1. Culbert H, Tu D, O'Brien DP, et al. HIV treatment in a conflict setting: outcomes and experience from Bukavu, Democratic Republic of Congo. Médecins Sans Frontiéres. PLoS Med 2007; 4:e129.
2. Lima VD, Gill VS, Yip B, Hogg RS, Montaner JS, Harrigan PR. Increased resilience to the development of drug resistance with modern boosted protease inhibitor- based highly active antiretroviral therapy. J Infect Dis 2008; 198:51-8.
3. Gupta RK, Hill A, Sawyer A, Pillay D. Emergence of drug resistance in HIV-1 infected patients after first-line highly active antiretroviral therapy (HAART): a systematic review of clinical trials [abstract O11]. HIV Med 2008; 9(Suppl 1):3-4.
4. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV infection. N Eng J Med 2008; 358: 2095-106.
5. Gazzard BG. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. BHIVA Treatment Guidelines Writing Group. HIV Med 2008; 9:563-608.